These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The rat biliary and urinary metabolism of the N6-methylated derivative of elliptinium acetate, and antitumor agent. Braham Y; Meunier G; Meunier B Drug Metab Dispos; 1988; 16(2):316-21. PubMed ID: 2898353 [TBL] [Abstract][Full Text] [Related]
3. Identification of the glucuronide and glutathione conjugates of the antitumor drug N2-methyl-9-hydroxyellipticinium acetate (Celiptium). Comparative disposition of this drug with its olivacinium isomer in rat bile. Maftouh M; Monsarrat B; Rao RC; Meunier B; Paoletti C Drug Metab Dispos; 1984; 12(1):111-9. PubMed ID: 6141901 [TBL] [Abstract][Full Text] [Related]
4. Peroxidase-catalysed oxidation of N2,N6-dimethyl-9-hydroxyellipticinium acetate. Evidence for the formation of an electrophilic quinone-iminium derivative. Meunier G; Bernadou J; Meunier B Biochem Pharmacol; 1987 Aug; 36(16):2599-604. PubMed ID: 3606658 [TBL] [Abstract][Full Text] [Related]
5. Covalent binding of the antitumor agent N2-methyl-9-hydroxy-ellipticinium acetate (NSC 264137) on RNA and poly A in vitro. Dugue B; Paoletti C; Meunier B Biochem Biophys Res Commun; 1984 Oct; 124(2):416-22. PubMed ID: 6388575 [TBL] [Abstract][Full Text] [Related]
6. Metabolism of the anti-tumour drugs N2-methyl-9-hydroxyellipticinium acetate (NSC 264137) and N2-methyl-9-hydroxyolivacinium acetate in the rat: preliminary identification of biliary 9-(O)-glucuronide and 10-(S)-glutathione conjugates. Maftouh M; Meunier G; Dugue B; Monsarrat B; Meunier B; Paoletti C Xenobiotica; 1983 May; 13(5):303-10. PubMed ID: 6636827 [TBL] [Abstract][Full Text] [Related]
7. Evidence for electrophilic properties of N2-methyl-9-hydroxy ellipticinium acetate (Celiptium) from human biliary metabolites. Bernadou J; Monsarrat B; Roche H; Armand JP; Paoletti C; Meunier B Cancer Chemother Pharmacol; 1985; 15(1):63-5. PubMed ID: 4006051 [TBL] [Abstract][Full Text] [Related]
8. Regioselective arylation of ribose in adenosine and guanosine with the antitumor drug N2-methyl-9-hydroxyellipticinium acetate. Bernadou J; Meunier B; Meunier G; Auclair C; Paoletti C Proc Natl Acad Sci U S A; 1984 Mar; 81(5):1297-301. PubMed ID: 6584882 [TBL] [Abstract][Full Text] [Related]
9. Nephrotoxicity of an ellipticine derivative (N2-methyl-9-hydroxyellipticinium acetate) in rat: a defect of urinary concentrating ability. Thomas N; Moulin B; Raguenez-Viotte G; Fillastre JP Ren Fail; 1991; 13(4):243-51. PubMed ID: 1780492 [TBL] [Abstract][Full Text] [Related]
10. Celiptium-induced nephrotoxicity and lipid peroxidation in rat renal cortex. Dadoun C; Raguenez-Viotte G Cancer Chemother Pharmacol; 1990; 27(3):178-86. PubMed ID: 2265453 [TBL] [Abstract][Full Text] [Related]
11. Renal toxicity of the antitumor drug N2-methyl-9-hydroxyellipticinium acetate in the Wistar rat. Raguenez-Viotte G; Dadoun C; Buchet P; Ducastelle T; Fillastre JP Arch Toxicol; 1988; 61(4):292-7. PubMed ID: 3377684 [TBL] [Abstract][Full Text] [Related]
12. Evidence for 4-hydroxyalkenals in rat renal cortex peroxidized by N2-methyl-9-hydroxyellipticinium acetate or Celiptium. Raguenez-Viotte G; Dieber-Rotheneder M; Dadoun C; Fillastre JP; Esterbauer H Biochim Biophys Acta; 1990 Oct; 1046(3):294-300. PubMed ID: 2145981 [TBL] [Abstract][Full Text] [Related]
13. Time course study of lipid peroxidation induced by N2-methyl-9-hydroxyellipticinium acetate or celiptium in rat renal cortex. Thomas N; Raguenez-Viotte G; Dieber-Rotheneder M; Esterbauer H; Fillastre JP Pharmacol Toxicol; 1991 Aug; 69(2):112-6. PubMed ID: 1775430 [TBL] [Abstract][Full Text] [Related]
14. omicron-Quinone formation in the biochemical oxidation of the antitumor drug N2-methyl-9-hydroxyellipticinium acetate. Bernadou J; Meunier G; Paoletti C; Meunier B J Med Chem; 1983 Apr; 26(4):574-9. PubMed ID: 6834391 [TBL] [Abstract][Full Text] [Related]
15. Bleb formation in the renal epithelial cell line LLC-PK1 exposed to N2-methyl-9-hydroxyellipticinium acetate (celiptium). Raguenez-Viotte G; Fillastre JP Int J Tissue React; 1990; 12(6):347-51. PubMed ID: 2102898 [TBL] [Abstract][Full Text] [Related]
16. Covalent binding of elliptinium acetate (NSC 264137) to nucleic acids of L1210 cells in culture. Dugue B; Auclair C; Meunier B Cancer Res; 1986 Aug; 46(8):3828-33. PubMed ID: 2425935 [TBL] [Abstract][Full Text] [Related]
17. Hemoglobin-catalyzed transformation of elliptinium acetate into electrophilic species. Evidences for oxidative activation of the drug in human red blood cells. Ha T; Bernadou J; Voisin E; Auclair C; Meunier B Chem Biol Interact; 1988; 65(1):73-84. PubMed ID: 3345574 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of 2-methyl-9-hydroxyellipticinium acetate (NSC-264137) in cancer patients (phase I study). Gouyette A; Huertas D; Droz JP; Rouesse J; Amiel JL Eur J Cancer Clin Oncol; 1982 Dec; 18(12):1285-92. PubMed ID: 6891926 [TBL] [Abstract][Full Text] [Related]
19. The biooxidation of cytotoxic ellipticine derivatives: a key to structure-activity relationship studies? Meunier G; De Montauzon D; Bernadou J; Grassy G; Bonnafous M; Cros S; Meunier B Mol Pharmacol; 1988 Jan; 33(1):93-102. PubMed ID: 3336351 [TBL] [Abstract][Full Text] [Related]
20. Subcellular localization of celiptium-induced peroxidative damage in rat renal cortex. Raguenez-Viotte G; Thomas N; Fillastre JP Arch Toxicol; 1991; 65(3):244-51. PubMed ID: 2053851 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]